IFNA1 and systemic lupus erythematosus: Patients with lupus were treated with rontalizumab in a phase one study that determined the antibody was safe and could reduce the expression of IFN-regulated genes; whereas similar results were obtained in a different trial evaluating the anti-IFNα monoclonal antibody sifalumimab [115,116].